TAUVID™ - First and Only FDA-approved tau PET imaging agent
Your patients and their families may have concerns that progressive cognitive decline is due to Alzheimer's disease. Now you have TAUVID to help.1
TAUVID is the first and only positron emission tomography (PET) brain imaging agent approved to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease.1-3
TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD.
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy.